Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo.

Sandholm J, Lehtimäki J, Ishizu T, Velu SE, Clark J, Härkönen P, Jukkola-Vuorinen A, Schrey A, Harris KW, Tuomela JM, Selander KS.

Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13570. [Epub ahead of print]

2.

Hydroxychalcone inhibitors of Streptococcus mutans glucosyl transferases and biofilms as potential anticaries agents.

Nijampatnam B, Casals L, Zheng R, Wu H, Velu SE.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3508-13. doi: 10.1016/j.bmcl.2016.06.033.

PMID:
27371109
3.

Mitochondrial thiol modification by a targeted electrophile inhibits metabolism in breast adenocarcinoma cells by inhibiting enzyme activity and protein levels.

Smith MR, Vayalil PK, Zhou F, Benavides GA, Beggs RR, Golzarian H, Nijampatnam B, Oliver PG, Smith RA, Murphy MP, Velu SE, Landar A.

Redox Biol. 2016 Aug;8:136-48. doi: 10.1016/j.redox.2016.01.002.

4.

Cyanobacterial Metabolite Calothrixins: Recent Advances in Synthesis and Biological Evaluation.

Xu S, Nijampatnam B, Dutta S, Velu SE.

Mar Drugs. 2016 Jan 12;14(1):17. doi: 10.3390/md14010017. Review.

5.

Channel Gating Regulation by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) First Cytosolic Loop.

Ehrhardt A, Chung WJ, Pyle LC, Wang W, Nowotarski K, Mulvihill CM, Ramjeesingh M, Hong J, Velu SE, Lewis HA, Atwell S, Aller S, Bear CE, Lukacs GL, Kirk KL, Sorscher EJ.

J Biol Chem. 2016 Jan 22;291(4):1854-65. doi: 10.1074/jbc.M115.704809.

PMID:
26627831
6.

Recent advances in isolation, synthesis, and evaluation of bioactivities of bispyrroloquinone alkaloids of marine origin.

Nijampatnam B, Dutta S, Velu SE.

Chin J Nat Med. 2015 Aug;13(8):561-77. doi: 10.1016/S1875-5364(15)30052-2. Review.

7.

Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats.

Yu JX, Voruganti S, Li DD, Qin JJ, Nag S, Xu S, Velu SE, Wang W, Zhang R.

Chin J Nat Med. 2015 Jul;13(7):554-60. doi: 10.1016/S1875-5364(15)30051-0.

8.

New small-molecule inhibitors of dihydrofolate reductase inhibit Streptococcus mutans.

Zhang Q, Nguyen T, McMichael M, Velu SE, Zou J, Zhou X, Wu H.

Int J Antimicrob Agents. 2015 Aug;46(2):174-82. doi: 10.1016/j.ijantimicag.2015.03.015.

9.

Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor.

Singh T, Gupta NA, Xu S, Prasad R, Velu SE, Katiyar SK.

Oncotarget. 2015 Aug 28;6(25):21268-82.

10.

A novel class of mitochondria-targeted soft electrophiles modifies mitochondrial proteins and inhibits mitochondrial metabolism in breast cancer cells through redox mechanisms.

Vayalil PK, Oh JY, Zhou F, Diers AR, Smith MR, Golzarian H, Oliver PG, Smith RA, Murphy MP, Velu SE, Landar A.

PLoS One. 2015 Mar 18;10(3):e0120460. doi: 10.1371/journal.pone.0120460.

11.

Total Synthesis of Calothrixins A and B via Oxidative Radical Reaction of Cyclohexenone with Aminophenanthridinedione.

Xu S, Nguyen T, Pomilio I, Vitale MC, Velu SE.

Tetrahedron. 2014 Sep 2;70(35):5928-5933.

12.

Antibacterial and Antibiofilm Activities of Makaluvamine Analogs.

Nijampatnam B, Nadkarni DH, Wu H, Velu SE.

Microorganisms. 2014;2(3):128-39. doi: 10.3390/microorganisms2030128.

13.

Total synthesis of zyzzyanones A-D.

Nadkarni DH, Murugesan S, Velu SE.

Tetrahedron. 2013 May 20;69(20):4105-4113.

14.

Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.

Chen D, Wang W, Qin JJ, Wang MH, Murugesan S, Nadkarni DH, Velu SE, Wang H, Zhang R.

Curr Cancer Drug Targets. 2013 Jul;13(6):651-60.

PMID:
23607596
15.

Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression.

Keeling KM, Wang D, Dai Y, Murugesan S, Chenna B, Clark J, Belakhov V, Kandasamy J, Velu SE, Baasov T, Bedwell DM.

PLoS One. 2013 Apr 10;8(4):e60478. doi: 10.1371/journal.pone.0060478.

16.

Mini-review: bmx kinase inhibitors for cancer therapy.

Jarboe JS, Dutta S, Velu SE, Willey CD.

Recent Pat Anticancer Drug Discov. 2013 Sep;8(3):228-38. Review.

PMID:
23198769
17.

Preclinical evaluation of anticancer efficacy and pharmacological properties of FBA-TPQ, a novel synthetic makaluvamine analog.

Zhang X, Xu H, Zhang X, Voruganti S, Murugesan S, Nadkarni DH, Velu SE, Wang MH, Wang W, Zhang R.

Mar Drugs. 2012 May;10(5):1138-55. doi: 10.3390/md10051138.

18.

Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action.

Chen T, Xu Y, Guo H, Liu Y, Hu P, Yang X, Li X, Ge S, Velu SE, Nadkarni DH, Wang W, Zhang R, Wang H.

PLoS One. 2011;6(6):e20729. doi: 10.1371/journal.pone.0020729.

19.

Elevated levels of NO are localized to distal airways in asthma.

Anderson JT, Zeng M, Li Q, Stapley R, Moore DR 2nd, Chenna B, Fineberg N, Zmijewski J, Eltoum IE, Siegal GP, Gaggar A, Barnes S, Velu SE, Thannickal VJ, Abraham E, Patel RP, Lancaster JR Jr, Chaplin DD, Dransfield MT, Deshane JS.

Free Radic Biol Med. 2011 Jun 1;50(11):1679-88. doi: 10.1016/j.freeradbiomed.2011.03.015. Erratum in: Free Radic Biol Med. 2013 May;58:45.

20.

Development and validation of an HPLC method for quantitation of BA-TPQ, a novel iminoquinone anticancer agent, and an initial pharmacokinetic study in mice.

Li H, Ezell SJ, Zhang X, Wang W, Xu H, Rayburn ER, Zhang X, Gurpinar E, Yang X, Sommers CI, Velu SE, Zhang R.

Biomed Chromatogr. 2011 May;25(5):628-34. doi: 10.1002/bmc.1498.

Items per page

Supplemental Content

Loading ...
Support Center